

Red Blood Cell Transfusions Should Be Preserved Just for Emergencies in Sick Cell Diseases

Mehmet Rami Helvaci^{1*}, Yusuf Aydin¹, Leyla Yilmaz Aydin², Alper Sevinc¹, Celalettin Camci¹, Abdulrazak Abyad³, & Lesley Pocock⁴

¹Specialist of Internal Medicine, MD, Turkey

²Specialist of Pulmonary Medicine, MD, Turkey

³Middle-East Academy for Medicine of Aging, MD, Lebanon

⁴Medi-WORLD International, Australia

*Corresponding author: Mehmet Rami Helvaci, 07400, Alanya, Turkey. 00-90-506-4708759

Submitted: 14 May 2025 Accepted: 19 May 2025 Published: 27 May 2025

doi <https://doi.org/10.63620/MK.JCMRRR.2025>

Citation: Helvaci, M. R., Aydin, Y., Aydin, L. Y., Sevinc, A., Camci, C., Abyad, A., & Pocock, L. (2025). Red Blood Cell Transfusions Should Be Preserved Just for Emergencies in Sick Cell Diseases. *J of Comp Med Res Rev Rep*, 2(3), 01-13.

Abstract

Background: Atherosclerosis may be the main cause of aging and death.

Methods: All patients with sickle cell diseases (SCD) were included.

Results: We studied 222 males and 212 females with mean ages of 30.8 vs 30.3 years, $p > 0.05$, respectively. Smoking (23.8% vs 6.1%, $p < 0.001$), alcohol (4.9% vs 0.4%, $p < 0.001$), transfused red blood cells (RBC) in their lifespans (48.1 vs 28.5 units, $p = 0.000$), disseminated teeth losses (5.4% vs 1.4%, $p < 0.001$), ileus (7.2% vs 1.4%, $p < 0.001$), cirrhosis (8.1% vs 1.8%, $p < 0.001$), chronic obstructive pulmonary disease (25.2% vs 7.0%, $p < 0.001$), coronary heart disease (CHD) (18.0% vs 13.2%, $p < 0.05$), leg ulcers (19.8% vs 7.0%, $p < 0.001$), clubbing (14.8% vs 6.6%, $p < 0.001$), chronic renal disease (9.9% vs 6.1%, $p < 0.05$), and stroke (12.1% vs 7.5%, $p < 0.05$) were all higher in males.

Conclusion: As an accelerated atherosclerotic process, hardened RBC-induced capillary endothelial damage initiating at birth terminates with multiorgan failures in early years of life in the SCD. Probably, stroke and CHD are the main causes of deaths even in the SCD. Probably, hydroxyurea is the most effective method of prevention of acute painful crises. On the other hand, RBC transfusions are the most effective treatments in acute painful crises both to decrease the severity of pain and to lower the risks of sudden deaths, probably due to the stroke or CHD, again. Because of the increased prevalences of allo-antibodies parallel to the increased number of transfusions, RBC transfusions should be preserved just for acute painful crises, surgical operations, births, and medical or surgical emergencies in the SCD.

Introduction

Chronic endothelial damage may be the main cause of aging and death by means of atherosclerotic multiorgan insufficiencies in human being [1]. Much higher blood pressures (BP) of the afferent vasculature may be the chief accelerating factor via recurrent injuries on vascular endothelium. Probably, whole afferent vasculature including capillaries are chiefly involved in the process.

Therefore venosclerosis or phlebosclerosis is not as famous as atherosclerosis in medicine. Due to the chronic endothelial injury, inflammation, edema, and fibrosis, vascular walls thicken, their lumens narrow, and they lose their elastic natures, those eventually reduce blood supply to terminal organs, and increase systolic and decrease diastolic BP further. Some of the well-known accelerating factors of the inflammatory process are sed-

entary lifestyle, physical inactivity, animal-rich diet, emotional stresses, smoking, alcohol, excess fat tissue, chronic inflammations, prolonged infections, and cancers for the development of terminal consequences including obesity, hypertension (HT), diabetes mellitus (DM), coronary heart disease (CHD), cirrhosis, chronic obstructive pulmonary disease (COPD), chronic renal disease (CRD), stroke, peripheral artery disease (PAD), mesenteric ischemia, osteoporosis, dementia, early aging, and premature death [2, 3]. Although early withdrawal of the accelerating factors can delay the above terminal consequences, after development of them, the endothelial changes can not be reversed, completely due to their fibrotic natures. The accelerating factors and terminal consequences of the vascular endothelial process are researched under the titles of metabolic syndrome, aging syndrome, and accelerated endothelial damage syndrome in medicine [4-6]. Similarly, sickle cell diseases (SCD) are chronic inflammatory and destructive processes on vascular endothelium, initiating at birth and terminating with an accelerated atherosclerosis-induced multiorgan failures in much earlier ages [7, 8]. Hemoglobin S causes loss of elastic and biconcave disc shaped structures of red blood cells (RBC). Probably loss of elasticity instead of shape is the main problem since sickling is rare in peripheral blood samples of cases with associated thalassemia minors (TM), and human survival is not affected in hereditary spherocytosis or elliptocytosis. Loss of elasticity is present during whole lifespan, but exaggerated with inflammations, infections, and additional stresses. The hardened RBC-induced chronic endothelial injury, inflammation, edema, and fibrosis terminate with tissue hypoxia in whole body [9]. As a difference from other causes of chronic endothelial damage, SCD keep vascular endothelium particularly at the capillary level since the capillary system is the major distributor of the hardened RBC into the tissues [10, 11]. The hardened RBC-induced chronic endothelial injury builds up an accelerated atherosclerosis in much earlier ages. Vascular narrowings and occlusions-induced tissue ischemia and multiorgan failures are the terminal consequences, so the mean life expectancy is decreased by 25 to 30 years for both genders in the SCD [8].

Material and Methods

The study was done in the Medical Faculty of the Mustafa Kemal University between March 2007 and June 2016. All cases with the SCD were studied. The SCD were diagnosed with the hemoglobin electrophoresis performed by means of high performance liquid chromatography (HPLC). Health histories including smoking, alcohol, acute painful crises per year, transfused units of RBC in their lifespans, leg ulcers, stroke, surgical procedures, deep venous thrombosis (DVT), epilepsy, and priapism were learnt. Cases with a history of one pack-year were accepted as smokers, and one drink-year were accepted as drinkers. A full physical examination was performed by the Same Internist, and cases with disseminated teeth losses (<20 teeth present) were noted. Patients with acute painful crises or other inflammatory events were treated at first, and the laboratory tests and clinical measurements were performed on the silent phase. Check up

procedures including serum iron, iron binding capacity, ferritin, creatinine, liver function tests, markers of hepatitis viruses A, B, and C, a posterior-anterior chest x-ray film, an electrocardiogram, a Doppler echocardiogram both to evaluate cardiac walls and valves, and to measure systolic BP of pulmonary artery, an abdominal ultrasonography, a venous Doppler ultrasonography of the lower limbs, a computed tomography (CT) of brain, and a magnetic resonance imaging (MRI) of hips were performed. Other bones for avascular necrosis were scanned according to the patients' complaints. So avascular necrosis of bones was diagnosed via MRI [12]. Associated TM were detected with serum iron, iron binding capacity, ferritin, and hemoglobin electrophoresis performed by means of HPLC because the SCD with associated TM come with milder clinics than the sickle cell anemia (SCA) (Hb SS) alone [13]. Systolic BP of the pulmonary artery of 40 mmHg or greater are accepted as pulmonary hypertension (PHT) [14]. Hepatic cirrhosis is diagnosed with full physical examination findings, laboratory parameters, and ultrasonographic evaluation. The criterion for diagnosis of COPD is a post-bronchodilator forced expiratory volume in one second/forced vital capacity of lower than 70% [15]. Acute chest syndrome (ACS) is detected clinically with the presence of new infiltrates on chest x-ray film, fever, cough, sputum production, dyspnea, and hypoxia [16]. An x-ray film of abdomen in upright position was taken just in patients with abdominal distention or discomfort, vomiting, obstipation, or lack of bowel movement, and ileus was diagnosed with gaseous distention of isolated segments of bowel, vomiting, obstipation, cramps, and with the absence of peristaltic activity. CRD is diagnosed with a continuous serum creatinine level of 1.3 mg/dL or higher in males and 1.2 mg/dL or higher in females. Digital clubbing is diagnosed with the ratio of distal phalangeal diameter to interphalangeal diameter of greater than 1.0, and with the presence of Schamroth's sign [17, 18]. An exercise electrocardiogram is taken in patients with an abnormal electrocardiogram and/or angina pectoris. Coronary angiography is performed for the exercise electrocardiogram positive patients. Eventually, CHD was diagnosed either angiographically or with the Doppler echocardiographic findings as movement abnormalities in the walls of heart. Rheumatic heart disease is detected with the echocardiographic findings, too. Stroke is diagnosed by the CT and MRI of the brain. Sickle cell retinopathy is diagnosed with ophthalmologic examination in cases with visual complaints. Mann-Whitney U test, Independent-Samples t test, and comparison of proportions were used as the methods of statistical analyses.

Results

The study included 222 males and 212 females with similar ages (30.8 vs 30.3 years, $p>0.05$, respectively), and there was no patient above the age of 59 years neither in males nor in females. Prevalences of associated TM were similar in males and females (72.5% vs 67.9%, $p>0.05$, respectively). Smoking (23.8% vs 6.1%) and alcohol (4.9% vs 0.4%) were both higher in males ($p<0.001$ for both).

Table 1: Characteristic features of the study patients

Variables	Males with the SCD*	p-value	Females with the SCD
Prevalence	51.1% (222)	Ns†	48.8% (212)
Mean age (year)	30.8 ± 10.0 (5-58)	Ns	30.3 ± 9.9 (8-59)

Associated TM‡	72.5% (161)	Ns	67.9% (144)
Smoking	23.8% (53)	<0.001	6.1% (13)
Alcoholism	4.9% (11)	<0.001	0.4% (1)

*Sickle cell diseases †Nonsignificant ($p>0.05$) ‡Thalassemia minors

Transfused units of RBC in their lifespans (48.1 vs 28.5, $p=0.000$), disseminated teeth losses (5.4% vs 1.4%, $p<0.001$), ileus (7.2% vs 1.4%, $p<0.001$), cirrhosis (8.1% vs 1.8%, $p<0.001$), COPD (25.2% vs 7.0%, $p<0.001$), CHD (18.0% vs 13.2%, $p<0.05$), leg ulcers (19.8% vs 7.0%, $p<0.001$), digital clubbing (14.8%

vs 6.6%, $p<0.001$), CRD (9.9% vs 6.1%, $p<0.05$), and stroke (12.1% vs 7.5%, $p<0.05$) were all higher in males, significantly. Although the mean age of mortality (30.2 vs 33.3 years) was lower in males, the difference was nonsignificant, probably due to the small sample size.

Table 2: Associated pathologies of the study patients

Variables	Males with the SCD*	p-value	Females with the SCD
Painful crises per year	5.0 ± 7.1 (0-36)	Ns†	4.9 ± 8.6 (0-52)
Transfused units of RBC‡	48.1 ± 61.8 (0-434)	0.000	28.5 ± 35.8 (0-206)
Disseminated teeth losses (<20 teeth present)	5.4% (12)	<0.001	1.4% (3)
CHD§	18.0% (40)	<0.05	13.2% (28)
Cirrhosis	8.1% (18)	<0.001	1.8% (4)
COPD¶	25.2% (56)	<0.001	7.0% (15)
Ileus	7.2% (16)	<0.001	1.4% (3)
Leg ulcers	19.8% (44)	<0.001	7.0% (15)
Digital clubbing	14.8% (33)	<0.001	6.6% (14)
CRD**	9.9% (22)	<0.05	6.1% (13)
Stroke	12.1% (27)	<0.05	7.5% (16)
PHT***	12.6% (28)	Ns	11.7% (25)
Autosplenectomy	50.4% (112)	Ns	53.3% (113)
DVT**** and/or varices and/or telangiectasias	9.0% (20)	Ns	6.6% (14)
Rheumatic heart disease	6.7% (15)	Ns	5.6% (12)
Avascular necrosis of bones	24.3% (54)	Ns	25.4% (54)
Sickle cell retinopathy	0.9% (2)	Ns	0.9% (2)
Epilepsy	2.7% (6)	Ns	2.3% (5)
ACS*****	2.7% (6)	Ns	3.7% (8)
Mortality	7.6% (17)	Ns	6.6% (14)
Mean age of mortality (year)	30.2 ± 8.4 (19-50)	Ns	33.3 ± 9.2 (19-47)

*Sickle cell diseases †Nonsignificant ($p>0.05$) ‡Red blood cells §Coronary heart disease ¶Chronic obstructive pulmonary disease **Chronic renal disease ***Pulmonary hypertension ****Deep venous thrombosis *****Acute chest syndrome

On the other hand, mean ages of the atherosclerotic consequences were shown in Table 3.

Table 3: Mean ages of consequences of the sickle cell diseases

Variables	Mean age (year)
Ileus	29.8 ± 9.8 (18-53)
Hepatomegaly	30.2 ± 9.5 (5-59)
ACS*	30.3 ± 10.0 (5-59)
Sickle cell retinopathy	31.5 ± 10.8 (21-46)
Rheumatic heart disease	31.9 ± 8.4 (20-49)
Autosplenectomy	32.5 ± 9.5 (15-59)
Disseminated teeth losses (<20 teeth present)	32.6 ± 12.7 (11-58)
Avascular necrosis of bones	32.8 ± 9.8 (13-58)
Epilepsy	33.2 ± 11.6 (18-54)

Priapism	33.4 ± 7.9 (18-51)
Left lobe hypertrophy of the liver	33.4 ± 10.7 (19-56)
Stroke	33.5 ± 11.9 (9-58)
COPD†	33.6 ± 9.2 (13-58)
PHT‡	34.0 ± 10.0 (18-56)
Leg ulcers	35.3 ± 8.8 (17-58)
Digital clubbing	35.4 ± 10.7 (18-56)
CHD§	35.7 ± 10.8 (17-59)
DVT¶ and/or varices and/or telangiectasias	37.0 ± 8.4 (17-50)
Cirrhosis	37.0 ± 11.5 (19-56)
CRD**	39.4 ± 9.7 (19-59)

*Acute chest syndrome †Chronic obstructive pulmonary disease ‡Pulmonary hypertension §Coronary heart disease ¶Deep venous thrombosis **Chronic renal disease

Discussion

Excess weight may be the most common cause of vasculitis, and actually the term should be replaced with excess fat tissue in medicine. Probably, obesity is one of the endpoints of the metabolic syndrome, since after development of obesity, nonpharmaceutical approaches provide little benefit either to reverse obesity or to prevent its consequences. Excess fat leads to a chronic and low-grade inflammatory process on vascular endothelium, and risk of death from all causes including cardiovascular diseases and cancers increases parallel to the range of excess fat [19]. The low-grade chronic inflammation may also cause genetic changes on the endothelial cells, and the systemic atherosclerosis may even decrease the clearance of malignant cells by natural killers [20]. The chronic inflammatory process is characterized by lipid-induced injury, invasion of macrophages, proliferation of smooth muscle cells, endothelial dysfunction, and increased atherogenicity [21, 22]. Excess fat is considered as a strong factor for controlling of C-reactive protein (CRP) concentration in serum, since excess fat tissue produces biologically active leptin, tumor necrosis factor- α , plasminogen activator inhibitor-1, and adiponectin-like cytokines [23, 24]. On the other hand, individuals with excess fat will also have an increased cardiac output. The prolonged increase in blood volume may aggravate myocardial hypertrophy and decrease cardiac compliance further. Beside the systemic atherosclerosis and HT, fasting plasma glucose (FPG) and serum cholesterol increased and high density lipoproteins (HDL) decreased parallel to the increased body mass index (BMI) [25]. Similarly, CHD and stroke increased parallel to the increased BMI [26]. Eventually, the risk of death from all causes increased parallel to the severity of excess fat in all age groups, and the cases with underweight may even have lower biological ages and longer survival [27]. Similarly, caloric restriction prolongs survival and retards age-related chronic diseases in human being [28].

Smoking may be the second most common cause of vasculitis. Probably, it causes a systemic inflammation on vascular endothelium terminating with an atherosclerosis-induced multiorgan failures in early years [29]. Its atherosclerotic effect is obvious in Buerger's disease and COPD [30]. Buerger's disease is an obliterative vasculitis in the small and medium-sized arteries and veins, and it has never been seen without smoking. Its characteristics are inflammation, fibrosis, and narrowing and occlusions

of arteries and veins, predominantly in hands and feet. Claudication is the most common symptom with a severe pain caused by insufficient blood supply in feet and hands, particularly during exercise. It typically begins in extremities but it may also radiate to central areas in advanced cases. Numbness or tingling of the limbs is also common. Skin ulcerations and gangrene of fingers or toes are the final consequences. Similar to the venous ulcers, diabetic ulcers, leg ulcers of the SCD, clubbing, onychomycosis, and delayed wound and fracture healings of the lower extremities, pooling of blood due to the gravity may be important in the development of Buerger's disease, particularly in the lower extremities. Multiple narrowings and occlusions in the arms and legs are diagnostic in the angiogram. Skin biopsies are rarely needed because a poorly perfused area will not heal, completely. Although most patients are heavy smokers, the limited smoking history of some patients may support the hypothesis that Buerger's disease may be an autoimmune reaction triggered by some constituent of tobacco. Although the only treatment way is complete cessation of smoking, the already developed narrowing and occlusions are irreversible. Due to the obvious role of inflammation, anti-inflammatory dose of aspirin in addition to the low-dose warfarin may be effective in prevention of microvascular infarctions of fingers and toes. On the other hand, FPG and HDL may be negative whereas triglycerides, low density lipoproteins (LDL), erythrocyte sedimentation rate, and CRP may be positive acute phase reactants in smokers [31]. Similarly, smoking was associated with the lower BMI values due to the systemic inflammatory effects [32, 33]. An increased heart rate was detected just after smoking even at rest [34]. Nicotine supplied by patch after smoking cessation decreased caloric intake in a dose-related manner [35]. Nicotine may lengthen intermeal time, and decrease amount of meal eaten [36]. Smoking may be associated with a postcessation weight gain, but the risk is the highest during the first year, and decreases with the following years [37]. Although the CHD was detected with similar prevalences in both genders, prevalences of smoking and COPD were higher in males against the higher prevalences of white coat hypertension, BMI, LDL, triglycerides, HT, and DM in females [38]. The prevalence of myocardial infarction is increased three-fold in men and six-fold in women with smoking, so smoking may be more dangerous for women probably due to the higher BMI [39]. Several toxic substances found in the cigarette smoke can affect various organ systems. For instance,

smoking is usually associated with depression, irritable bowel syndrome (IBS), chronic gastritis, hemorrhoids, and urolithiasis with several mechanisms [40]. First of all, smoking may have some antidepressive effects. Secondly, smoking-induced vascular inflammation may disturb epithelial functions for absorption and excretion in the gastrointestinal (GI) and genitourinary (GU) tracts [41]. Thirdly, diarrheal losses-induced urinary changes may cause urolithiasis [42]. Fourthly, smoking-induced sympathetic nervous system activation may cause motility problems in the GI and GU tracts terminating with IBS and urolithiasis. Eventually, immunosuppression secondary to smoking-induced vascular inflammation may terminate with the GI and GU tract infections causing urolithiasis since some types of bacteria can provoke urinary supersaturation, and modify the environment to form crystal deposits. Actually, 10% of urinary stones are struvite stones which are built by magnesium ammonium phosphate produced by the bacteria, producing urease. So, urolithiasis was seen in 17.9% of cases with IBS and 11.6% of cases without ($p < 0.01$) [40].

Beside the stroke, CHD is the other terminal cause of death in human being. The most common triggering event is the disruption of an atherosclerotic plaque in an epicardial coronary artery, which leads to a clotting cascade. The plaque is a gradual and unstable collection of lipids, fibrous tissue, and white blood cells (WBC), particularly the macrophages in arterial walls in decades. Stretching and relaxation of arteries with each heart beat increases mechanical shear stress on atheromas to rupture. After the myocardial infarction, a collagen scar tissue takes its place which may also cause life threatening arrhythmias since the scar tissue conducts electrical impulses more slowly. The difference in conduction velocity between the injured and uninjured tissue can trigger re-entry or a feedback loop that is believed to be the cause of lethal arrhythmias. Ventricular fibrillation is the most serious arrhythmia that is the leading cause of sudden cardiac death. It is an extremely fast and chaotic heart rhythm. Ventricular tachycardia may also cause sudden cardiac death that usually results in rapid heart rates preventing effective cardiac pumping. Cardiac output and BP may fall to dangerous levels which can lead to further coronary ischemia and extension of the infarct. This scar tissue may even cause ventricular aneurysm, rupture, and sudden cardiac death. Aging, physical inactivity, sedentary lifestyle, animal-rich diet, excess fat tissue, emotional stresses, smoking, alcohol, prolonged infections, chronic inflammations, and cancers are important in atherosclerotic plaque formation. Moderate physical exercise is associated with a 50% reduced incidence of CHD [43]. Probably, excess fat tissue may be the most important cause of CHD since there are nearly 20 kg of excess fat tissue between the lower and upper borders of normal weight, 33 kg between the obesity, 66 kg between the morbid obesity ($BMI \geq 40 \text{ kg/m}^2$), and 81 kg between the super obesity ($BMI \geq 45 \text{ kg/m}^2$) in adults. In fact, there is a huge percentage of adults with a heavier fat mass than their organ plus muscle masses that brings a heavy stress both on the heart and brain.

Cirrhosis is the 10th leading cause of death for men and the 12th for women in the United States [6]. Although the improvements of health services worldwide, the increased morbidity and mortality of cirrhosis may be explained by prolonged survival of the human being, and increased prevalence of excess weight, globally. For example, nonalcoholic fatty liver disease (NAFLD)

affects up to one third of the world population, and it became the most common cause of chronic liver disease even at childhood at the moment [44]. NAFLD is a marker of pathological fat deposition combined with a low-grade inflammation that results with hypercoagulability, endothelial dysfunction, and an accelerated atherosclerosis [44]. Beside terminating with cirrhosis, NAFLD is associated with higher overall mortality rates as well as increased prevalences of CHD and stroke [45]. Authors reported independent associations between NAFLD and impaired flow-mediated vasodilation and increased mean carotid artery intima-media thickness (CIMT) [46]. NAFLD may be considered as one of the hepatic consequences of the metabolic syndrome and SCD [47]. Probably smoking also takes role in the inflammatory process of the capillary endothelium in the liver because the systemic inflammatory effects of smoking on the endothelial cells is obvious in Buerger's disease and COPD [36]. Increased oxidative stress, inactivation of antiproteases, and release of proinflammatory mediators may terminate with the systemic atherosclerosis in smokers. The atherosclerotic effects of alcohol is more prominent in hepatic endothelium probably due to the highest concentrations of its metabolites in the liver. Chronic infectious and inflammatory processes and cancers may also terminate with an accelerated atherosclerotic process [48]. For example, chronic hepatitis C virus (HCV) infection raised CIMT, and normalization of hepatic function with HCV clearance may be secondary to reversal of favourable lipids observed with the chronic infection [49]. As a result, cirrhosis may also be another atherosclerotic consequence of the metabolic syndrome and SCD, again.

Acute painful crises are the severest symptoms of the SCD. Although some authors reported that pain itself may not be life threatening directly, infections, medical or surgical emergencies, or emotional stresses are the most common precipitating factors of the crises [50]. The increased basal metabolic rate during such stresses aggravates the sickling, capillary endothelial damage, inflammation, edema, tissue hypoxia, and multiorgan insufficiencies. So the risk of mortality is much higher during such crises. Actually, each crisis may complicate with the following crises by leaving sequelae on the capillary endothelial system in whole body. After a period of time, the sequelae may terminate with sudden multiorgan failures and death with a final crisis that may even not be severe, clinically. Similarly, after a 20-year experience on such patients, the deaths seem sudden and unexpected events in the SCD. Unfortunately, most of the deaths develop just after the hospital admission, and majority of them are patients without hydroxyurea therapy [51, 52]. Rapid RBC supports are usually life-saving for such patients, although preparation of RBC units for transfusion usually takes time. Beside that RBC supports in emergencies become much more difficult in terminal cases due to the repeated transfusions-induced blood group mismatch. Actually, transfusion of each unit of RBC complicates the following transfusions by means of the blood subgroup mismatch. Due to the significant efficacy of hydroxyurea therapy, RBC transfusions should be preserved just for acute painful crises, surgical operations, births, and medical or surgical emergencies in the SCD [51, 52]. According to our experiences, simple and repeated transfusions are superior to RBC exchange in the SCD [53, 54]. First of all, preparation of one or two units of RBC suspensions in each time rather than preparation of six units or higher provides time to clinicians to prepare more units

by preventing sudden death of such high-risk patients. Secondly, transfusions of one or two units of RBC suspensions in each time decrease the severity of pain, and relax anxiety of the patients and their relatives since RBC transfusions probably have the strongest analgesic effects during the crises [55]. Actually, the decreased severity of pain by transfusions also indicates the decreased severity of inflammation all over the body. Thirdly, transfusions of lesser units of RBC suspensions in each time by means of the simple transfusions will decrease transfusion-related complications including infections, iron overload, and blood group mismatch in the future. Fourthly, transfusion of RBC suspensions in the secondary health centers may prevent some deaths developed during the transport to the tertiary centers for the exchange. Finally, cost of the simple transfusions on insurance system is much lower than the exchange that needs trained staff and additional devices. On the other hand, pain is the result of complex and poorly understood interactions between RBC, WBC, platelets (PLT), and endothelial cells, yet. Whether leukocytosis contributes to the pathogenesis by releasing cytotoxic enzymes is unknown. The adverse effects of WBC on vascular endothelium are of particular interest for atherosclerotic consequences in the SCD. For example, leukocytosis even in the absence of any infection was an independent predictor of the severity of the SCD [56], and it was associated with the risk of stroke [57]. Disseminated tissue hypoxia, releasing of inflammatory mediators, bone infarctions, and activation of afferent nerves may take role in the pathophysiology of the intolerable pain. Due to the severity of pain, narcotic analgesics are usually needed [58], but according to our practice, simple and repeated RBC transfusions may be highly effective both to relieve pain and to prevent sudden deaths that may develop secondary to the stroke or CHD on the chronic atherosclerotic background of the SCD, again.

Hydroxyurea may be the only life-saving drug for the treatment of the SCD. It interferes with the cell division by blocking the formation of deoxyribonucleotides via inhibition of ribonucleotide reductase. The deoxyribonucleotides are the building blocks of DNA. Hydroxyurea mainly affects hyperproliferating cells. Although the action way of hydroxyurea is thought to be the increase in gamma-globin synthesis for fetal hemoglobin (Hb F), its main action may be the suppression of leukocytosis and thrombocytosis by blocking the DNA synthesis in the SCD [59, 60]. By this way, the chronic inflammatory and destructive process of the SCD is suppressed with some extent. Due to the same action way, hydroxyurea is also used in moderate and severe psoriasis to suppress hyperproliferating skin cells. As in the viral hepatitis cases, although presence of a continuous damage of sickle cells on the capillary endothelium, the severity of destructive process is probably exaggerated by the patients' own WBC and PLT. So suppression of proliferation of them may limit the endothelial damage-induced edema, ischemia, and infarctions in whole body [61]. Similarly, final Hb F levels in hydroxyurea users did not differ from their pretreatment levels [62]. The Multicenter Study of Hydroxyurea (MSH) studied 299 severely affected adults with the SCA, and compared the results of patients treated with hydroxyurea or placebo [63]. The study particularly researched effects of hydroxyurea on painful crises, ACS, and requirement of blood transfusion. The outcomes were so overwhelming in the favour of hydroxyurea that the study was terminated after 22 months, and hydroxyurea was initiated

for all patients. The MSH also demonstrated that patients treated with hydroxyurea had a 44% decrease in hospitalizations [63]. In multivariable analyses, there was a strong and independent association of lower neutrophil counts with the lower crisis rates [63]. But this study was performed just in severe SCA cases alone, and the rate of painful crises was decreased from 4.5 to 2.5 per year [63]. Whereas we used all subtypes of the SCD with all clinical severity, and the rate of painful crises was decreased from 10.3 to 1.7 per year ($p < 0.000$) with an additional decreased severity of them (7.8/10 vs 2.2/10, $p < 0.000$) (51). Parallel to us, adult patients using hydroxyurea for frequent painful crises appear to have reduced mortality rate after a 9-year follow-up period [64]. Although the underlying disease severity remains critical to determine prognosis, hydroxyurea may also decrease severity of disease and prolong survival [64]. The complications start to be seen even in infancy in the SCD. For example, infants with lower hemoglobin values were more likely to have higher incidences of ACS, painful crises, and lower neuropsychological scores, and hydroxyurea reduced the incidences of them [65]. If started in early years of life, hydroxyurea may protect splenic function, improve growth, and prevent multiorgan insufficiencies. Although RBC transfusions can also reduce the complications, there are the risks of infections, iron overload, and development of allo-antibodies causing subsequent transfusions much more difficult. Therefore RBC transfusions should be kept in hands just for emergencies as the most effective weapon at the moment.

Aspirin is a member of nonsteroidal anti-inflammatory drugs (NSAID). Although aspirin has similar anti-inflammatory effects with the other NSAID, it also suppresses the normal functions of PLT, irreversibly. This property causes aspirin being different from other NSAID, which are reversible inhibitors. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a serine residue in the active site of the cyclooxygenase (COX) enzyme. Aspirin inactivates the COX enzyme, irreversibly, which is required for the synthesis of prostaglandins (PG) and thromboxanes (TX). PG are the locally produced hormones with some diverse effects, including the transmission of pain into the brain and modulation of the hypothalamic thermostat and inflammation. TX are responsible for the aggregation of PLT to form blood clots. In another definition, low-dose aspirin irreversibly blocks the formation of TXA₂ in the PLT, producing an inhibitory effect on the PLT aggregation during whole lifespan of the affected PLT (8-9 days). Since PLT do not have nucleus and DNA, they are unable to synthesize new COX enzyme once aspirin has inhibited the enzyme. But aspirin does not decrease the blood viscosity. The antithrombotic property of aspirin is useful to reduce the risks of myocardial infarction, transient ischemic attack, and stroke [66]. Heart attacks are caused primarily by blood clots, and low-dose of aspirin is seen as an effective medical intervention to prevent a second myocardial infarction [67]. According to the literature, aspirin may also be effective in prevention of colorectal cancers [68]. On the other hand, aspirin has some side effects including gastric ulcers, gastric bleeding, worsening of asthma, and Reye syndrome in childhood and adolescence. Due to the risk of Reye syndrome, the US Food and Drug Administration recommends that aspirin should not be prescribed for febrile patients under the age of 12 years [69]. Eventually, the general recommendation to use aspirin in children has been withdrawn, and it was only recommended for Kawasaki

disease [70]. Reye syndrome is a rapidly worsening brain disease [70]. The first detailed description of Reye syndrome was in 1963 by an Australian pathologist, Douglas Reye [71]. The syndrome mostly affects children, but it can only affect fewer than one in a million children a year [71]. Symptoms of Reye syndrome may include personality changes, confusion, seizures, and loss of consciousness [70]. Although the liver toxicity typically occurs in the syndrome, jaundice is usually not seen with it, but the liver is enlarged in most cases [70]. Although the death occurs in 20-40% of affected cases, about one third of survivors get a significant degree of brain damage [70]. It usually starts just after recovery from a viral infection, such as influenza or chicken pox. About 90% of cases in children are associated with an aspirin use [71, 72]. Inborn errors of metabolism are also the other risk factors, and the genetic testing for inborn errors of metabolism became available in developed countries in the 1980s [70]. When aspirin use was withdrawn for children in the US and UK in the 1980s, a decrease of more than 90% in rates of Reye syndrome was seen [71]. The treatment is supportive. Mannitol can be used for the brain swelling [71]. Due to the very low risk of Reye syndrome but much higher risk of death due to the SCD in children, aspirin should be added both into the acute and chronic phase treatments with an anti-inflammatory dose even in childhood in the SCD [73].

Warfarin is an anticoagulant, and it is found in the List of Essential Medicines of WHO. In 2020, it was the 58th most commonly prescribed medication in the United States. It does not reduce blood viscosity. Warfarin is used to decrease the tendency for thrombosis, and it can prevent formation of blood clots and reduce the risk of embolism. Warfarin is the best suited for anticoagulation in areas of slowly flowing blood such as in veins and the pooled blood behind artificial and natural valves, and in blood pooled in dysfunctional cardiac atria. It is commonly used to prevent blood clots in the circulatory system such as DVT and pulmonary embolism, and to protect against stroke in atrial fibrillation (AF), valvular heart disease, or artificial heart valves. Less commonly, it is used following ST-segment elevation myocardial infarction and orthopedic surgery. The warfarin initiation regimens are simple, safe, and suitable to be used in ambulatory and in patient settings [74]. Warfarin should be initiated with a 5 mg dose, or 2 to 4 mg in the elderly. In the protocol of low-dose warfarin, the target international normalised ratio (INR) value is between 2.0 and 2.5, whereas in the protocol of standard-dose warfarin, the target INR value is between 2.5 and 3.5 [75]. When warfarin is used and INR is in therapeutic range, simple discontinuation of the drug for five days is enough to reverse the effect, and causes INR to drop below 1.5 [76]. Its effects can be reversed with phytonadione (vitamin K1), fresh frozen plasma, or prothrombin complex concentrate, rapidly. Blood products should not be routinely used to reverse warfarin overdose, when vitamin K1 could work alone. Warfarin decreases blood clotting by blocking vitamin K epoxide reductase, an enzyme that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anti-clotting protein C and protein S are also inhibited, but to a lesser degree. A few days are required for full effect to occur, and these effects can last for up to five days. The consensus agrees that current self-testing and management devices are effective methods of monitoring oral anticoagulation therapy, providing outcomes possibly better than achieved, clinically. The only common side

effect of warfarin is hemorrhage. The risk of severe bleeding is low with a yearly rate of 1-3% [77]. All types of bleeding may occur, but the severest ones are those involving the central nervous system [76]. The risk is particularly increased once the INR exceeds 4.5 [77]. The risk of bleeding is increased further when warfarin is combined with antiplatelet drugs such as clopidogrel or aspirin [78]. But thirteen publications from 11 cohorts including more than 48,500 patients with more than 11,600 warfarin users were included in the meta-analysis [79]. In patients with AF and non-end-stage CRD, warfarin resulted in a lower risk of ischemic stroke ($p=0.004$) and mortality ($p<0.00001$), but had no effect on major bleeding ($p>0.05$) [79]. Similarly, warfarin is associated with significant reductions in ischemic stroke even in patients with warfarin-associated intracranial hemorrhage (ICH) [80]. Whereas recurrent ICH occurred in 6.7% of patients who used warfarin and 7.7% of patients who did not use warfarin without any significant difference in between ($p>0.05$) [80]. On the other hand, patients with cerebral venous thrombosis (CVT) those were anticoagulated either with warfarin or dabigatran had low risk of recurrent venous thrombotic events (VTE), and the risk of bleeding was similar in both regimens, suggesting that both warfarin and dabigatran are safe and effective for preventing recurrent VTE in cases with CVT [81]. Additionally, an INR value of 1.5 achieved with an average daily dose of 4.6 mg warfarin, has resulted in no increase in the number of men ever reporting minor bleeding episodes [82]. Non-rheumatic AF increases the risk of stroke, presumably from atrial thromboemboli, and long-term low-dose warfarin therapy is highly effective and safe in preventing stroke in them [83]. There were just two strokes in the warfarin group (0.41% per year) as compared with 13 strokes in the control group (2.98% per year) with a reduction of 86% in the risk of stroke ($p=0.0022$) [83]. The mortality was markedly lower in the warfarin group, too ($p=0.005$) [83]. The frequencies of bleedings that required hospitalization or transfusion were the same in both groups ($p>0.05$) [83]. Additionally, very-low-dose warfarin was safe and effective for prevention of thromboembolism in metastatic breast cancer [84]. The average daily dose was 2.6 mg, and the mean INR was 1.5 [84]. On the other hand, new oral anticoagulants had a favourable risk-benefit profile with significant reductions in stroke, ICH, and mortality, and with similar major bleedings as for warfarin, but increased GI bleeding [85]. Interestingly, rivaroxaban and low-dose apixaban were associated with increased risks of all cause mortality compared with warfarin [86]. The mortality rates were 4.1%, 3.7%, and 3.6% per year in the warfarin, 110 mg of dabigatran, and 150 mg of dabigatran groups ($p>0.05$ for both) in AF in another study, respectively [87]. On the other hand, infections, medical or surgical emergencies, and emotional stresses-induced increased basal metabolic rate accelerates sickling, and an exaggerated capillary endothelial edema-induced myocardial infarction and stroke may cause sudden deaths [88]. So lifelong aspirin with an anti-inflammatory dose plus low-dose warfarin may be a life-saving regimen even at childhood to decrease severity of capillary inflammation and to prevent thromboembolic events in the SCD [89].

COPD is the third leading cause of death in the world [90, 91]. Aging, smoking, alcohol, male gender, excess fat tissue, chronic inflammations, prolonged infections, and cancers may be the major causes. Atherosclerotic effects of smoking may be the most obvious in the COPD and Buerger's disease, probably due

to the higher concentrations of toxic substances in the lungs and pooling of blood in the extremities. After smoking, excess fat tissue may be the second common cause of COPD due to the excess fat tissue-induced atherosclerotic process in whole body. Regular alcohol consumption may be the third leading cause of the systemic accelerated atherosclerotic process and COPD, since COPD was one of the most common diagnoses in alcohol dependence [92]. Furthermore, 30-day readmission rates were higher in the COPD patients with alcoholism [93]. Probably an accelerated atherosclerotic process is the main structural background of functional changes that are characteristics of the COPD. The inflammatory process of vascular endothelium is enhanced by release of various chemicals by inflammatory cells, and it terminates with an advanced fibrosis, atherosclerosis, and pulmonary losses. COPD may actually be the pulmonary consequence of the systemic atherosclerotic process. Since beside the accelerated atherosclerotic process of the pulmonary vasculature, there are several reports about coexistence of associated endothelial inflammation all over the body in COPD [94]. For example, there may be close relationships between COPD, CHD, PAD, and stroke [95]. Furthermore, two-third of mortality cases were caused by cardiovascular diseases and lung cancers in the COPD, and the CHD was the most common cause in a multi-center study of 5.887 smokers [96]. When the hospitalizations were researched, the most common causes were the cardiovascular diseases, again [96]. In another study, 27% of mortality cases were due to the cardiovascular diseases in the moderate and severe COPD [97]. On the other hand, COPD may be the pulmonary consequence of the systemic atherosclerotic process caused by the hardened RBC in the SCD [90].

Leg ulcers are seen in 10% to 20% of the SCD [98]. Its prevalence increases with aging, male gender, and SCA [99]. The leg ulcers have an intractable nature, and around 97% of them relapse in a period of one year [98]. Similar to Buerger's disease, the leg ulcers occur in the distal segments of the body with a lesser collateral blood flow [98]. The hardened RBC-induced chronic endothelial damage, inflammation, edema, and fibrosis at the capillaries may be the major causes [99]. Prolonged exposure to the hardened bodies due to the pooling of blood in the lower extremities may also explain the leg but not arm ulcers in the SCD. The hardened RBC-induced venous insufficiencies may also accelerate the process by pooling of causative bodies in the legs, and vice versa. Pooling of blood may also be important for the development of venous ulcers, diabetic ulcers, Buerger's disease, clubbing, and onychomycosis in the lower extremities. Furthermore, pooling of blood may be the cause of delayed wound and fracture healings in the lower extremities. Smoking and alcohol may also have some additional atherosclerotic effects on the leg ulcers in males. Hydroxyurea is the first drug that was approved by Food and Drug Administration in the SCD [100]. It is an oral, cheap, safe, and effective drug that blocks cell division by suppressing formation of deoxyribonucleotides which are the building blocks of DNA [11]. Its main action may be the suppression of hyperproliferative WBC and PLT in the SCD [101]. Although presence of a continuous damage of hardened RBC on vascular endothelium, severity of the destructive process is probably exaggerated by immune systems. Similarly, lower WBC counts were associated with lower crises rates, and if a tissue infarct occurs, lower WBC counts may decrease severity of tissue damage and pain [62]. Prolonged resolution of leg

ulcers with hydroxyurea may also suggest that the ulcers may be secondary to increased WBC and PLT counts-induced exaggerated capillary endothelial inflammation and edema.

Digital clubbing is characterized by the increased normal angle of 165° between nailbed and fold, increased convexity of the nail fold, and thickening of the whole distal finger [102]. Although the exact cause and significance is unknown, the chronic tissue hypoxia is highly suspected [103]. In the previous study, only 40% of clubbing cases turned out to have significant underlying diseases while 60% remained well over the subsequent years [18]. But according to our experiences, digital clubbing is frequently associated with the pulmonary, cardiac, renal, and hepatic diseases and smoking which are characterized with chronic tissue hypoxia [5]. As an explanation for that hypothesis, lungs, heart, kidneys, and liver are closely related organs which affect their functions in a short period of time. On the other hand, digital clubbing is also common in the SCD, and its prevalence was 10.8% in the present study. It probably shows chronic tissue hypoxia caused by disseminated endothelial damage, inflammation, edema, and fibrosis at the capillary level in the SCD. Beside the effects of SCD, smoking, alcohol, cirrhosis, CRD, CHD, and COPD, the higher prevalence of digital clubbing in males (14.8% vs 6.6%, $p < 0.001$) may also show some additional role of male gender in the systemic atherosclerotic process.

CRD is also increasing all over the world that can also be explained by aging of the human being and increased prevalence of excess weight [104]. Aging, animal-rich diet, excess fat tissue, smoking, alcohol, inflammatory and infectious processes, and cancers may be the major causes of the renal endothelial inflammation. The inflammatory process is enhanced by release of various chemicals by lymphocytes to repair the damaged endothelial cells of the renal arteriols. Due to the continuous irritation of the vascular endothelial cells, prominent changes develop in the architecture of the renal tissues with advanced atherosclerosis, tissue hypoxia, and infarcts [105]. Excess fat tissue-induced hyperglycemia, dyslipidemia, elevated BP, and insulin resistance can cause tissue inflammation and immune cell activation [106]. For example, age ($p = 0.04$), high-sensitivity CRP ($p = 0.01$), mean arterial BP ($p = 0.003$), and DM ($p = 0.02$) had significant correlations with the CIMT [104]. Increased renal tubular sodium reabsorption, impaired pressure natriuresis, volume expansion due to the activations of sympathetic nervous system and renin-angiotensin system, and physical compression of kidneys by visceral fat tissue may be some mechanisms of the increased BP with excess weight [107]. Excess fat tissue also causes renal vasodilation and glomerular hyperfiltration which initially serve as compensatory mechanisms to maintain sodium balance due to the increased tubular reabsorption [107]. However, along with the increased BP, these changes cause a hemodynamic burden on the kidneys in long term that causes chronic endothelial damage [108]. With prolonged excess fat tissue, there are increased urinary protein excretion, loss of nephron function, and exacerbated HT. With the development of dyslipidemia and DM, CRD progresses much more easily [107]. On the other hand, the systemic inflammatory effects of smoking on endothelial cells may also be important in the CRD [109]. Although some authors reported that alcohol was not related with the CRD [109], various metabolites of alcohol circulate in blood vessels of kidneys and give harm to the endothelium. Chronic inflammatory and infectious

processes may also terminate with the accelerated atherosclerosis in the renal vasculature [108]. Due to the systemic nature of atherosclerosis, there are close relationships between CRD and other atherosclerotic consequences of the metabolic syndrome including CHD, COPD, PAD, cirrhosis, and stroke [110, 111]. For example, the most common causes of death were the CHD and stroke in the CRD again [112]. The hardened RBC-induced capillary endothelial damage may be the main cause of CRD in the SCD, again [113].

Beside the CHD, stroke is the other terminal cause of death, and it develops as an acute thromboembolic event on the chronic atherosclerotic background. Aging, male gender, smoking, alcohol, and excess fat tissue may be the major underlying causes. Stroke is also a common complication of the SCD [114]. Similar to the leg ulcers, stroke is particularly higher in the SCA and cases with higher WBC counts [115]. Sickling-induced capillary endothelial damage, activations of WBC, PLT, and coagulation system, and hemolysis may terminate with chronic capillary endothelial inflammation, edema, and fibrosis [116]. Probably, stroke may not have a macrovascular origin in the SCD, and diffuse capillary endothelial inflammation, edema, and fibrosis may be much more important. Infections, inflammations, medical or surgical emergencies, and emotional stress may precipitate stroke by increasing basal metabolic rate and sickling. A significant reduction of stroke with hydroxyurea may also suggest that a significant proportion of cases is developed due to the increased WBC and PLT counts-induced capillary endothelial inflammation and edema [117].

Conclusion

As a conclusion, hardened RBC-induced capillary endothelial damage initiating at birth terminates with multiorgan failures in early years of life in the SCD. Probably, stroke and CHD are the main causes of deaths even in the SCD. Probably, hydroxyurea is the most effective method of prevention of acute painful crises. On the other hand, RBC transfusions are the most effective treatments in acute painful crises both to decrease the severity of pain and to lower the risks of sudden deaths, probably due to the stroke or CHD, again. Due to the increased prevalences of allo-antibodies parallel to the increased number of transfusions, RBC transfusions should be preserved just for acute painful crises, surgical operations, births, and medical or surgical emergencies in the SCD.

References

- Widlansky, M. E., Gokce, N., Keaney, J. F., Jr., & Vita, J. A. (2003). The clinical implications of endothelial dysfunction. *Journal of the American College of Cardiology*, 42(7), 1149–1160.
- Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). The metabolic syndrome. *The Lancet*, 365(9468), 1415–1428.
- Franklin, S. S., Barboza, M. G., Pio, J. R., & Wong, N. D. (2006). Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. *Journal of Hypertension*, 24(10), 2009–2016.
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*, 106(25), 3143–3421.
- Helvacı, M. R., Aydin, L. Y., & Aydin, Y. (2012). Digital clubbing may be an indicator of systemic atherosclerosis even at microvascular level. *HealthMED*, 6(12), 3977–3981.
- Anderson RN, Smith BL. Deaths: leading causes for 2001. *Natl Vital Stat Rep* 2003; 52(9): 1-85.
- Helvacı, M. R., Gokce, C., Davran, R., Akkucuk, S., Ugur, M., & Oruc, C. (2015). Mortal quintet of sickle cell diseases. *International Journal of Clinical and Experimental Medicine*, 8(7), 11442–11448.
- Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., et al. (1994). Mortality in sickle cell disease: Life expectancy and risk factors for early death. *The New England Journal of Medicine*, 330(23), 1639–1644.
- Helvacı, M. R., Yaprak, M., Abyad, A., & Pocock, L. (2018). Atherosclerotic background of hepatosteatosis in sickle cell diseases. *World Family Medicine*, 16(3), 12–18.
- Helvacı, M. R., & Kaya, H. (2011). Effect of sickle cell diseases on height and weight. *Pakistan Journal of Medical Sciences*, 27(2), 361–364.
- Helvacı, M. R., Aydin, Y., & Ayyildiz, O. (2013). Hydroxyurea may prolong survival of sickle cell patients by decreasing frequency of painful crises. *HealthMED*, 7(8), 2327–2332.
- Mankad, V. N., Williams, J. P., Harpen, M. D., Mancı, E., Longenecker, G., & Moore, R. B. (1990). Magnetic resonance imaging of bone marrow in sickle cell disease: Clinical, hematologic, and pathologic correlations. *Blood*, 75(1), 274–283.
- Helvacı, M. R., Aydin, Y., & Ayyildiz, O. (2013). Clinical severity of sickle cell anemia alone and sickle cell diseases with thalassemias. *HealthMED*, 7(7), 2028–2033.
- Fisher, M. R., Forfia, P. R., Chamera, E., Houston-Harris, T., Champion, H. C., Girgis, R. E., et al. (2009). Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, 179(7), 615–621.
- Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., et al. (2013). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *American Journal of Respiratory and Critical Care Medicine*, 187(4), 347–365.
- Davies, S. C., Luce, P. J., Win, A. A., Riordan, J. F., & Brozovic, M. (1984). Acute chest syndrome in sickle-cell disease. *The Lancet*, 1(8367), 36–38.
- Vandemergel X, Renneboog B. Prevalence, aetiologies and significance of clubbing in a department of general internal medicine. *Eur J Intern Med* 2008; 19(5): 325-9.
- Schamroth, L. (1976). Personal experience. *South African Medical Journal*, 50(9), 297–300.
- Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C., & Heath, C. W., Jr. (1999). Body-mass index and mortality in a prospective cohort of U.S. adults. *The New England Journal of Medicine*, 341(15), 1097–1105.
- Helvacı, M. R., Aydin, Y., & Gundogdu, M. (2012). Smoking induced atherosclerosis in cancers. *HealthMED*, 6(11), 3744–3749.

21. Ross, R. (1999). Atherosclerosis—An inflammatory disease. *The New England Journal of Medicine*, 340(2), 115–126.
22. Ridker, P. M. (2001). High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. *Circulation*, 103(13), 1813–1818.
23. Danesh, J., Collins, R., Appleby, P., & Peto, R. (1998). Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. *JAMA*, 279(18), 1477–1482.
24. Visser, M., Bouter, L. M., McQuillan, G. M., Wener, M. H., & Harris, T. B. (1999). Elevated C-reactive protein levels in overweight and obese adults. *JAMA*, 282(22), 2131–2135.
25. Zhou, B., Wu, Y., Yang, J., Li, Y., Zhang, H., & Zhao, L. (2002). Overweight is an independent risk factor for cardiovascular disease in Chinese populations. *Obesity Reviews*, 3(3), 147–156.
26. Zhou, B. F. (2002). Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases—Report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. *Biomedical and Environmental Sciences*, 15(3), 245–252.
27. Helvaci, M. R., Kaya, H., Yalcin, A., & Kuvandik, G. (2007). Prevalence of white coat hypertension in underweight and overweight subjects. *International Heart Journal*, 48(5), 605–613.
28. Heilbronn, L. K., & Ravussin, E. (2003). Calorie restriction and aging: Review of the literature and implications for studies in humans. *American Journal of Clinical Nutrition*, 78(3), 361–369.
29. Fodor, J. G., Tzerovska, R., Dorner, T., & Rieder, A. (2004). Do we diagnose and treat coronary heart disease differently in men and women? *Wiener Medizinische Wochenschrift*, 154(17–18), 423–425.
30. Helvaci, M. R., Aydin, L. Y., & Aydin, Y. (2012). Chronic obstructive pulmonary disease may be one of the terminal end points of metabolic syndrome. *Pakistan Journal of Medical Sciences*, 28(3), 376–379.
31. Helvaci, M. R., Kayabasi, Y., Celik, O., Sencan, H., Abyad, A., & Pocock, L. (2023). Smoking causes a moderate or severe inflammatory process in human body. *American Journal of Biomedical Science & Research*, 7(6), 694–702.
32. Grunberg, N. E., Greenwood, M. R., Collins, F., Epstein, L. H., Hatsukami, D., & Niaura, R. (1992). National working conference on smoking and body weight. Task Force 1: Mechanisms relevant to the relations between cigarette smoking and body weight. *Health Psychology*, 11, 4–9.
33. Helvaci, M. R., Camci, C., Nisa, E. K., Ersahin, T., Atabay, A., Alrawii, I., Ture, Y., Abyad, A., & Pocock, L. (2024). Severity of sickle cell diseases restricts smoking. *Annals of Medical and Medical Research*, 7, 1074.
34. Walker, J. F., Collins, L. C., Rowell, P. P., Goldsmith, L. J., Moffatt, R. J., & Stamford, B. A. (1999). The effect of smoking on energy expenditure and plasma catecholamine and nicotine levels during light physical activity. *Nicotine & Tobacco Research*, 1(4), 365–370.
35. Hughes, J. R., & Hatsukami, D. K. (1997). Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight. *Journal of Substance Abuse*, 9, 151–159.
36. Miyata, G., Meguid, M. M., Varma, M., Fetissov, S. O., & Kim, H. J. (2001). Nicotine alters the usual reciprocity between meal size and meal number in female rat. *Physiology & Behavior*, 74(1–2), 169–176.
37. Froom, P., Melamed, S., & Benbassat, J. (1998). Smoking cessation and weight gain. *Journal of Family Practice*, 46(6), 460–464.
38. Helvaci, M. R., Kaya, H., & Gundogdu, M. (2012). Gender differences in coronary heart disease in Turkey. *Pakistan Journal of Medical Sciences*, 28(1), 40–44.
39. Prescott, E., Hippe, M., Schnohr, P., Hein, H. O., & Vestbo, J. (1998). Smoking and risk of myocardial infarction in women and men: longitudinal population study. *BMJ*, 316(7137), 1043–1047.
40. Helvaci, M. R., Kabay, S., & Gulcan, E. (2006). A physiologic events' cascade, irritable bowel syndrome, may even terminate with urolithiasis. *Journal of Health Sciences*, 52(4), 478–481.
41. Helvaci, M. R., Dede, G., Yildirim, Y., Salaz, S., Abyad, A., & Pocock, L. (2019). Smoking may even cause irritable bowel syndrome. *World Family Medicine*, 17(3), 28–33.
42. Helvaci, M. R., Algin, M. C., & Kaya, H. (2009). Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis. *Eurasian Journal of Medicine*, 41(3), 158–161.
43. Kamimura, D., Loprinzi, P. D., Wang, W., Suzuki, T., Butler, K. R., Mosley, T. H., et al. (2017). Physical activity is associated with reduced left ventricular mass in obese and hypertensive African Americans. *American Journal of Hypertension*, 30(6), 617–623.
44. Bhatia, L. S., Curzen, N. P., Calder, P. C., & Byrne, C. D. (2012). Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? *European Heart Journal*, 33(10), 1190–1200.
45. Pacifico, L., Nobili, V., Anania, C., Verdecchia, P., & Chiesa, C. (2011). Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. *World Journal of Gastroenterology*, 17(26), 3082–3091.
46. Mawatari, S., Uto, H., & Tsubouchi, H. (2011). Chronic liver disease and arteriosclerosis. *Nihon Rinsho*, 69(1), 153–157.
47. Bugianesi, E., Moscatiello, S., Ciaravella, M. F., & Marchesini, G. (2010). Insulin resistance in nonalcoholic fatty liver disease. *Current Pharmaceutical Design*, 16(17), 1941–1951.
48. Mostafa, A., Mohamed, M. K., Saeed, M., Hasan, A., Fontanet, A., Godslan, I., et al. (2010). Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. *Gut*, 59(8), 1135–1140.
49. Helvaci, M. R., Ayyildiz, O., Gundogdu, M., Aydin, Y., Abyad, A., & Pocock, L. (2018). Hyperlipoproteinemias may actually be acute phase reactants in the plasma. *World Family Medicine*, 16(1), 7–10.
50. Parfrey, N. A., Moore, W., & Hutchins, G. M. (1985). Is pain crisis a cause of death in sickle cell disease? *American Journal of Clinical Pathology*, 84, 209–212.
51. Helvaci, M. R., Ayyildiz, O., & Gundogdu, M. (2014). Hydroxyurea therapy and parameters of health in sickle cell patients. *HealthMED*, 8(4), 451–456.
52. Helvaci, M. R., Tonyali, O., Yaprak, M., Abyad, A., & Pocock, L. (2019). Increased sexual performance of sickle cell patients with hydroxyurea. *World Family Medicine*, 17(4), 28–33.

53. Helvacı, M. R., Atci, N., Ayyildiz, O., Muftuoğlu, O. E., & Pocock, L. (2016). Red blood cell supports in severe clinical conditions in sickle cell diseases. *World Family Medicine*, 14(5), 11–18.
54. Helvacı, M. R., Ayyildiz, O., & Gundogdu, M. (2013). Red blood cell transfusions and survival of sickle cell patients. *HealthMED*, 7(11), 2907–2912.
55. Helvacı, M. R., Cayir, S., Halici, H., Sevinc, A., Camci, C., Abyad, A., & Pocock, L. (2024). Red blood cell transfusions may have the strongest analgesic effect during acute painful crises in sickle cell diseases. *Annals of Clinical Medicine and Case Reports*, 13(12), 1–12.
56. Miller, S. T., Sleeper, L. A., Pegelow, C. H., Enos, L. E., Wang, W. C., Weiner, S. J., et al. (2000). Prediction of adverse outcomes in children with sickle cell disease. *New England Journal of Medicine*, 342, 83–89.
57. Balkaran, B., Char, G., Morris, J. S., Thomas, P. W., Serjeant, B. E., & Serjeant, G. R. (1992). Stroke in a cohort of patients with homozygous sickle cell disease. *Journal of Pediatrics*, 120, 360–366.
58. Cole, T. B., Sprinkle, R. H., Smith, S. J., & Buchanan, G. R. (1986). Intravenous narcotic therapy for children with severe sickle cell pain crisis. *American Journal of Diseases of Children*, 140, 1255–1259.
59. Miller, B. A., Platt, O., Hope, S., Dover, G., & Nathan, D. G. (1987). Influence of hydroxyurea on fetal hemoglobin production in vitro. *Blood*, 70(6), 1824–1829.
60. Platt, O. S. (1988). Is there treatment for sickle cell anemia? *New England Journal of Medicine*, 319(22), 1479–1480.
61. Helvacı, M. R., Aydoğan, F., Sevinc, A., Camci, C., & Dilek, I. (2014). Platelet and white blood cell counts in severity of sickle cell diseases. *Prensa Médica Argentina*, 100(1), 49–56.
62. Charache, S. (1997). Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. *Seminars in Hematology*, 34(3), 15–21.
63. Charache, S., Barton, F. B., Moore, R. D., Terrin, M. L., Steinberg, M. H., Dover, G. J., et al. (1996). Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *Medicine (Baltimore)*, 75(6), 300–326.
64. Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., et al. (2003). Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. *JAMA*, 289(13), 1645–1651.
65. Lebensburger, J. D., Miller, S. T., Howard, T. H., Casella, J. F., Brown, R. C., Lu, M., et al. (2012). Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study. *Pediatric Blood & Cancer*, 59(4), 675–678.
66. Toghi, H., Konno, S., Tamura, K., Kimura, B., & Kawano, K. (1992). Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. *Stroke*, 23(10), 1400–1403.
67. Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. *Lancet*, 373(9678), 1849–1860.
68. Algra, A. M., & Rothwell, P. M. (2012). Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. *Lancet Oncology*, 13(5), 518–527.
69. Macdonald, S. (2002). Aspirin use to be banned in under 16 year olds. *BMJ*, 325(7371), 988.
70. Schrör, K. (2007). Aspirin and Reye syndrome: A review of the evidence. *Paediatric Drugs*, 9(3), 195–204.
71. Pugliese, A., Beltramo, T., & Torre, D. (2008). Reye's and Reye's-like syndromes. *Cell Biochemistry and Function*, 26(7), 741–746.
72. Hurwitz, E. S. (1989). Reye's syndrome. *Epidemiologic Reviews*, 11, 249–253.
73. Meremikwu, M. M., & Okomo, U. (2011). Sickle cell disease. *BMJ Clinical Evidence*, 2011, 2402.
74. Mohamed, S., Fong, C. M., Ming, Y. J., Kori, A. N., Wahab, S. A., & Ali, Z. M. (2021). Evaluation of an initiation regimen of warfarin for international normalized ratio target 2.0 to 3.0. *Journal of Pharmacy Technology*, 37(6), 286–292.
75. Chu, M. W. A., Ruel, M., Graeve, A., Gerdisch, M. W., Ralph, J., Damiano Jr, R. J., & Smith, R. L. (2023). Low-dose vs standard warfarin after mechanical mitral valve replacement: A randomized trial. *Annals of Thoracic Surgery*, 115(4), 929–938.
76. Crowther, M. A., Douketis, J. D., Schnurr, T., Steidl, L., Mera, V., Ulteriori, C., et al. (2002). Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial. *Annals of Internal Medicine*, 137(4), 251–254.
77. Brown, D. G., Wilkerson, E. C., & Love, W. E. (2015). A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. *Journal of the American Academy of Dermatology*, 72(3), 524–534.
78. Delaney, J. A., Opatrny, L., Brophy, J. M., & Suissa, S. (2007). Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. *CMAJ*, 177(4), 347–351.
79. Dahal, K., Kunwar, S., Rijal, J., Schulman, P., & Lee, J. (2016). Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: A meta-analysis of observational studies. *Chest*, 149(4), 951–959.
80. Chai-Adisaksopha, C., Lorio, A., Hillis, C., Siegal, D., Witt, D. M., Schulman, S., et al. (2017). Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. *Thrombosis Research*, 160, 97–104.
81. Ferro, J. M., Coutinho, J. M., Dentali, F., Kobayashi, A., Alasheev, A., Canhão, P., et al. (2019). Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: A randomized clinical trial. *JAMA Neurology*, 76(12), 1457–1465.
82. Meade, T. W. (1990). Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. *American Journal of Cardiology*, 65(6), 7C–11C.

83. Singer, D. E., Hughes, R. A., Gress, D. R., Sheehan, M. A., Oertel, L. B., Maraventano, S. W., et al. (1990). The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *New England Journal of Medicine*, 323(22), 1505–1511.
84. Levine, M., Hirsh, J., Gent, M., Arnold, A., Warr, D., Falanya, A., et al. (1994). Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. *Lancet*, 343(8902), 886–889.
85. Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., et al. (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. *Lancet*, 383(9921), 955–962.
86. Vinogradova, Y., Coupland, C., Hill, T., & Hippisley-Cox, J. (2018). Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: Cohort study in primary care. *BMJ*, 362, k2505.
87. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine*, 361(12), 1139–1151.
88. Helvacı, M. R., Cayir, S., Halici, H., Sevinc, A., Camci, C., Abyad, A., & Pocock, L. (2024). Terminal endpoints of systemic atherosclerotic processes in sickle cell diseases. *World Family Medicine*, 22(5), 13–23.
89. Helvacı, M. R., Daglioglu, M. C., Halici, H., Sevinc, A., Camci, C., Abyad, A., & Pocock, L. (2024). Low-dose aspirin plus low-dose warfarin may be the standard treatment regimen in Buerger's disease. *World Family Medicine*, 22(6), 22–35.
90. Helvacı, M. R., Erden, E. S., & Aydin, L. Y. (2013). Atherosclerotic background of chronic obstructive pulmonary disease in sickle cell patients. *HealthMED*, 7(2), 484–488.
91. Rennard, S. I., & Drummond, M. B. (2015). Early chronic obstructive pulmonary disease: Definition, assessment, and prevention. *Lancet*, 385(9979), 1778–1788.
92. Schoepf, D., & Heun, R. (2015). Alcohol dependence and physical comorbidity: Increased prevalence but reduced relevance of individual comorbidities for hospital-based mortality during a 12.5-year observation period in general hospital admissions in urban North-West England. *European Psychiatry*, 30(4), 459–468.
93. Singh, G., Zhang, W., Kuo, Y. F., & Sharma, G. (2016). Association of psychological disorders with 30-day readmission rates in patients with COPD. *Chest*, 149(4), 905–915.
94. Mannino, D. M., Watt, G., Hole, D., Gillis, C., Hart, C., McConnachie, A., et al. (2006). The natural history of chronic obstructive pulmonary disease. *European Respiratory Journal*, 27(3), 627–643.
95. Mapel, D. W., Hurley, J. S., Frost, F. J., Petersen, H. V., Picchi, M. A., & Coultas, D. B. (2000). Health care utilization in chronic obstructive pulmonary disease: A case-control study in a health maintenance organization. *Archives of Internal Medicine*, 160(17), 2653–2658.
96. Anthonisen, N. R., Connett, J. E., Enright, P. L., & Manfreda, J. (2002). Hospitalizations and mortality in the Lung Health Study. *American Journal of Respiratory and Critical Care Medicine*, 166(3), 333–339.
97. McGarvey, L. P., John, M., Anderson, J. A., Zvarich, M., & Wise, R. A. (2007). Ascertainment of cause-specific mortality in COPD: Operations of the TORCH Clinical Endpoint Committee. *Thorax*, 62(5), 411–415.
98. Trent, J. T., & Kirsner, R. S. (2004). Leg ulcers in sickle cell disease. *Advances in Skin & Wound Care*, 17(8), 410–416.
99. Minniti, C. P., Eckman, J., Sebastiani, P., Steinberg, M. H., & Ballas, S. K. (2010). Leg ulcers in sickle cell disease. *American Journal of Hematology*, 85(10), 831–833.
100. Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., et al. (2014). Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. *JAMA*, 312(10), 1033–1045.
101. Helvacı, M. R., Aydogan, F., Sevinc, A., Camci, C., & Dilek, I. (2014). Platelet and white blood cell counts in severity of sickle cell diseases. *HealthMED*, 8(4), 477–482.
102. Myers, K. A., & Farquhar, D. R. (2001). The rational clinical examination: Does this patient have clubbing? *JAMA*, 286(3), 341–347.
103. Toovey, O. T., & Eisenhauer, H. J. (2010). A new hypothesis on the mechanism of digital clubbing secondary to pulmonary pathologies. *Medical Hypotheses*, 75(6), 511–513.
104. Nassiri, A. A., Hakemi, M. S., Asadzadeh, R., Faizei, A. M., Alatab, S., Miri, R., et al. (2012). Differences in cardiovascular disease risk factors associated with maximum and mean carotid intima-media thickness among hemodialysis patients. *Iranian Journal of Kidney Diseases*, 6(3), 203–208.
105. Helvacı, M. R., Gokce, C., Sahan, M., Hakimoglu, S., Coskun, M., & Gozukara, K. H. (2016). Venous involvement in sickle cell diseases. *International Journal of Clinical and Experimental Medicine*, 9(6), 11950–11957.
106. Xia, M., Guerra, N., Sukhova, G. K., Yang, K., Miller, C. K., Shi, G. P., et al. (2011). Immune activation resulting from NKG2D/ligand interaction promotes atherosclerosis. *Circulation*, 124(25), 2933–2943.
107. Hall, J. E., Henegar, J. R., Dwyer, T. M., Liu, J., da Silva, A. A., Kuo, J. J., et al. (2004). Is obesity a major cause of chronic kidney disease? *Advances in Renal Replacement Therapy*, 11(1), 41–54.
108. Nerpin, E., Ingelsson, E., Risérus, U., Helmersson-Karlqvist, J., Sundström, J., Jobs, E., et al. (2012). Association between glomerular filtration rate and endothelial function in an elderly community cohort. *Atherosclerosis*, 224(1), 242–246.
109. Stengel, B., Tarver-Carr, M. E., Powe, N. R., Eberhardt, M. S., & Brancati, F. L. (2003). Lifestyle factors, obesity and the risk of chronic kidney disease. *Epidemiology*, 14(4), 479–487.
110. Bonora, E., & Targher, G. (2012). Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. *Nature Reviews Gastroenterology & Hepatology*, 9(7), 372–381. <https://doi.org/10.1038/nrgastro.2012.41>
111. Helvacı, M. R., Cayir, S., Halici, H., Sevinc, A., Camci, C., Sencan, H., Davran, R., Abyad, A., & Pocock, L. (2024). Acute chest syndrome and coronavirus disease may actually be genetically determined exaggerated immune response syndromes particularly in pulmonary capillaries. *World Family Medicine*, 22(3), 6–16.

112. Tonelli, M., Wiebe, N., Culleton, B., House, A., Rabbat, C., Fok, M., et al. (2006). Chronic kidney disease and mortality risk: A systematic review. *Journal of the American Society of Nephrology*, 17(7), 2034–2047. <https://doi.org/10.1681/ASN.2005101085>
113. Helvacı, M. R., Aydın, Y., & Aydın, L. Y. (2013). Atherosclerotic background of chronic kidney disease in sickle cell patients. *HealthMED*, 7(9), 2532–2537.
114. DeBaun, M. R., Gordon, M., McKinstry, R. C., Noetzel, M. J., White, D. A., Sarnaik, S. A., et al. (2014). Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. *New England Journal of Medicine*, 371(8), 699–710. <https://doi.org/10.1056/NEJMoa1401731>
115. Majumdar, S., Miller, M., Khan, M., Gordon, C., Forsythe, A., Smith, M. G., et al. (2014). Outcome of overt stroke in sickle cell anaemia: A single institution's experience. *British Journal of Haematology*, 165(5), 707–713. <https://doi.org/10.1111/bjh.12801>.
116. Kossorotoff, M., Grevent, D., & de Montalembert, M. (2014). Cerebral vasculopathy in pediatric sickle-cell anemia. *Archives de Pédiatrie*, 21(4), 404–414. <https://doi.org/10.1016/j.arcped.2014.01.026>.
117. Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., et al. (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. *New England Journal of Medicine*, 332(20), 1317–1322. <https://doi.org/10.1056/NEJM199505183322001>.